REMARKS

In the Office Action of February 23, 2006, the Examiner has restricted the pending claims 84-95 into two groups:

> Group I: claims 84-93, and 95 drawn to a method of solid phase peptide synthesis; and
>
> Group II: claim 94, drawn to a ligand presenting assembly.

Applicant will elect Group I with traverse. The Examiner indicated in the Office Action that should Group I be elected, Applicant is to elect a single species from the following groups:

> A. Formula I (length of amino acids);
>
> B. Formula II; and
>
> C. Peptide sequences from claim 90 or 95, i.e. a single peptide sequence.

Applicant will elect the following species:

> A. The C terminal sequence of OspC from Borrelia burgdorferi (H-Pro-Val-Val-Ala-Glu-Ser-Pro-Lys-Lys-Pro-OH (10 amino acids) as the peptide of the formula H_2N-A-COOH;
>
> B. Imino diacetic acid as the species of Formula II; and

C. LPA-I of the formula FmocN(CH_2CO-Pro-Val-Val-Ala-Glu-Ser-Pro-Lys-Lys-Pro-OH)$_2$ as the peptide sequence from claim 90 or 95.

Applicant traverses the restriction requirement because (1) the process of Group I can only be used to make the LPA of Group II and (2) Applicant is not certain that use of an alternative known synthetic process, other than Applicant's solid phase synthetic method, could prepare the LPA of Group II, i.e. antigen peptides in a ligand presenting assembly in a C-terminal orientation, of claim 94. As such, these two groups of inventions are not distinct, and the restriction requirement should be withdrawn.

If the Examiner has any questions regarding this response, the Examiner is invited to telephone undersigned counsel at the number provided below.

Respectfully submitted,
JACOBSON HOLMAN PLLC

By _____
Joseph G. Contrera
Reg. No. 44,678

400 Seventh St., N.W.
Washington, D.C. 20004
(202) 638-6666
Date: March 16, 2006
HBJ:JGC:gm